DOCSLIB.ORG

Circulating Levels of Plasminogen Activator Inhibitor Type-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Circulating Levels of Plasminogen Activator Inhibitor Type-1 J Am Soc Nephrol 12: 1255–1263, 2001 Circulating Levels of Plasminogen Activator Inhibitor Type-1, Tissue Plasminogen Activator, and Thrombomodulin in Hemodialysis Patients: Biochemical Correlations and Role as Independent Predictors of Coronary Artery Stenosis ALFONS SEGARRA,* PILAR CHACON,´ † CRISTINA MARTINEZ-EYARRE,‡ XAVIER ARGELAGUER,* JOSEFA VILA,* PILAR RUIZ,* JOAN FORT,* JORGE BARTOLOME,*´ JOAQUIN CAMPS,* ERNESTO MOLINER,§ ANTONI PELEGR´I,࿣ FERNANDO MARCO,¶ ANTONIO OLMOS,* and LLUIS PIERA* *Servicios de Nefrologı´a and †Bioquı´mica, Hospital Valle Hebro´n, Barcelona; ‡CDR Monolab, §Unidad de Hemodia´lisis, Hospital Sant Gervasi; ࿣Centro de Nefrologı´a, Virgen de Montserrat; and ¶Centro de Dia´lisis Nephros, Barcelona, Spain. Abstract. This study investigated the relationship between the extent with major classic vascular risk factors and to a lesser circulating levels of the endothelial cell glycoproteins plasmin- extent with CRP and serum triglycerides. Forty-six patients ogen activator inhibitor type 1 (PAI-1), tissue plasminogen (23%) had evidence of CAD. Variables associated with CAD activator (TPA), and thrombomodulin (TM) and the major in the univariate analysis included age, time on dialysis, male vascular risk factors described in dialysis patients. In addition, gender, number of packs of cigarettes per year, high BP, the role of these endothelial cell products as independent fibrinogen, apolipoprotein B, albumin, PAI-1 activity, CRP, predictors of coronary artery disease (CAD) was analyzed. thrombin-antithrombin complexes, and fibrinopeptide A. Lo- Levels of TM, TPA antigen (Ag), TPA activity, PAI-1 Ag, gistic regression analysis found age, high-density lipoprotein PAI-1 activity, TPA/PAI complexes, thrombin-antithrombin cholesterol, gender, high BP, CRP, time on dialysis, and PAI-1 complexes, fibrinopeptide A, C-reactive protein (CRP), inter- activity to be independent predictors of CAD. This model leukin-1␤ and tumor necrosis factor-␣, lipids, apoproteins A1 classified correctly 85% of patients as having CAD and and B, and albumin were measured in a group of 200 nondi- showed adequate goodness of fit for all risk categories. Our abetic dialysis patients and 100 healthy matched volunteers. data support a pathogenic link among activated inflammatory When compared with healthy controls, dialysis patients response, endothelial injury, and CAD in hemodialysis patients showed increased levels of CRP, TM, TPA, and PAI-1 and and suggest that assessment of circulating PAI-1 levels could evidence of increased thrombin-dependent fibrin formation. be an additional tool to identify dialysis patients who are at risk Increased levels of active PAI-1 were associated to a great for developing atheromatous cardiovascular disease. Central to the response-to-injury hypothesis is the proposal that vidual patients, some of them are elevated significantly in the different vascular risk factors somehow lead to endothelial disorders with acute endothelial damage and may provide cell injury, which can elicit a series of cellular interactions that reliable correlations in large population studies (3–8). In recent culminate in the lesions of atherosclerosis (1). Several endo- years, it has been shown clearly that circulating levels of PAI-1 thelial products have been proposed as possible in vivo markers and other endothelial cell glycoproteins are increased in hemo- of the endothelial cell injury, such as von Willebrand factor, dialysis patients (9–13). Although this increase has been con- thrombomodulin (TM), tissue plasminogen activator (TPA), sidered as a subclinical sign of endothelial cell injury (9,12), plasminogen activator inhibitor (PAI), and soluble p-selectin this association is merely a hypothesis that remains to be (2–5). Although all of these markers lack sensitivity and/or proved. Before the circulating levels of PAI-1 and other endo- specificity for assessment of endothelial dysfunction in indi- thelial glycoproteins are considered as indicators of a chronic endothelium activated state, other potential mechanisms that contribute to the increased levels of these endothelial products Received July 19, 2000. Accepted November 1, 2000. should be taken into account. First, it is widely known that Correspondence to Dr. Alfons Segarra Medrano, Unidad de Investigacio´n, PAI-1 may behave as an acute-phase reactant (14). Second, Servicio de Nefrologı´a, Hospital Valle Hebro´n, Passeig Vall d’Hebro´n, 119- certain studies suggest that PAI-1 activity in chronic renal 129, E-08035 Barcelona, Spain. Phone: 34-93-274 61 52; Fax: 34-93-274 62 04; E-mail: [email protected] failure and dialysis patients is associated strongly with the 1046-6673/1206-1255 common metabolic abnormalities of obesity and hyperlipid- Journal of the American Society of Nephrology emia (15). Moreover, if circulating endothelial glycoproteins Copyright © 2001 by the American Society of Nephrology such as PAI-1, TPA, and TM are subclinical markers of endo- 1256 Journal of the American Society of Nephrology J Am Soc Nephrol 12: 1255–1263, 2001 thelial cell injury, then the levels of these molecules should be PAI-1 activities were determined by chromogenic assays (Biopool, statistically associated with major classical vascular risk fac- Umea, Sweden). Fibrinopeptide A (FPA) was determined by ELISA tors and/or with the presence of atheromatous cardiovascular (Boehringer Mannheim GmbH; Diagnostica Stago). C-reactive pro- disease. tein (CRP) was determined by the Behring Nephelometry immuno- This study was designed (1) to investigate the relationship assay (NA latex CRO, Behring Institute, Galway, Ireland). Serum interleukin-1␤ (IL-1␤) and tumor necrosis factor-␣ (TNF␣) were between the circulating levels of the endothelial cell glycop- determined by ELISA (Medgenix Diagnostics, Brussels, Belgium). roteins PAI 1, TPA, and TM and the major vascular risk factors Albumin concentration was determined by the green bromcresol described in dialysis patients and (2) to determine the role of method. these endothelial cell products as independent predictors of All assays were performed in duplicate and calibrated with purified CAD in a large group of nondiabetic dialysis patients. standards and reference plasmas from the manufacturers. Intra- and interassay coefficients of variation for all tests were determined with Materials and Methods the use of 20 different plasma samples. Patients To avoid the influence of acute intercurrent diseases on the bio- chemical parameters, we carried out analyses at least 6 mo after the We studied 200 nondiabetic patients who were receiving dialysis clinical event in all patients who required hospitalization for acute treatment in three outpatient dialysis centers affiliated with our ne- illness or infections (n ϭ 6) or who had surgical procedures (n ϭ 4), phrology department. The study group consisted of 120 men and 80 episodes of kidney allograft rejection (n ϭ 2), or acute vascular women, 31 to 80 yr old, dialyzed three times a week for 4 to 200 mo. thrombosis (n ϭ 1) before being entered in the study. The hemodialysis prescription was 9 to 13.5 h/wk, with the use of a A prerequisite for including the levels of endothelial cell glycop- 1.2- to 1.6-m cuprophane hollow-fiber filter and bicarbonate dialysate roteins, CRP, and inflammatory cytokines in statistical analyses was containing 2 g/L glucose. The dialyzers were not reused. All patients to demonstrate that the predialysis levels of all of these variables received a multivitamin supplement after the dialysis sessions, includ- showed little variation over time when measured in the same group of ing vitamins C and B and folic acid. A total of 140 patients (70%) patients. For this purpose, we analyzed the variation coefficients for received erythropoietin therapy, 70 patients (35%) received antiplate- the different variables in 30 random patients before the start of four let drugs (aspirin or ticlopidine), 65 patients (32.5%) were treated with consecutive dialysis sessions. They were as follows: TPA Ag, 12%; angiotensin-converting enzyme inhibitors (ACEI), and 34 patients PAI-1 Ag, 16%; PAI-1 activity, 14%; FPA, 8.4%; TAT complexes, (17%) received therapy with simvastatin or pravastatin. 12.3%; CRP, 11%; IL1-␤, 26%; TNF-␣, 20%; and soluble TM, 9.8%. The cause of chronic renal failure was glomerular disease in 70 patients (35%), interstitial nephritis in 30 patients (15%), polycystic kidney disease in 35 patients (17.5%), vascular disease in 20 patients Clinical Data Collection (10%), and unknown in 45 patients (22.5%). Information on risk factors was obtained by medical record review, The control group comprised 100 healthy, age- and gender- personal interview, and physical examination. Coronary angiography matched volunteers who were recruited from among the population of was performed on all patients who had no previous episodes of healthy people living in the geographic area of our center. well-documented acute myocardial infarction and who experienced The study protocol was accepted by the ethics committee of our clinical symptoms that suggested ischemic heart disease associated hospital, and all patients gave their written informed consent before with ST changes in the ECG. participation. Definitions Laboratory Procedures CAD was diagnosed in the presence of one of the following: (1) For lipid and apoprotein assays, blood was collected from the definitive episode of myocardial infarction with appropriate rise in antecubital vein in glass tubes with no additives after an overnight
Load more

Recommended publications
  • Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism
    International Journal of Molecular Sciences Review Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism Michał Z ˛abczyk 1,2 , Joanna Natorska 1,2 and Anetta Undas 1,2,* 1 John Paul II Hospital, 31-202 Kraków, Poland; [email protected] (M.Z.); [email protected] (J.N.) 2 Institute of Cardiology, Jagiellonian University Medical College, 31-202 Kraków, Poland * Correspondence: [email protected]; Tel.: +48-12-614-30-04; Fax: +48-12-614-21-20 Abstract: Coagulation factor XIII (FXIII) is converted by thrombin into its active form, FXIIIa, which crosslinks fibrin fibers, rendering clots more stable and resistant to degradation. FXIII affects fibrin clot structure and function leading to a more prothrombotic phenotype with denser networks, characterizing patients at risk of venous thromboembolism (VTE). Mechanisms regulating FXIII activation and its impact on fibrin structure in patients with acute VTE encompassing pulmonary embolism (PE) or deep vein thrombosis (DVT) are poorly elucidated. Reduced circulating FXIII levels in acute PE were reported over 20 years ago. Similar observations indicating decreased FXIII plasma activity and antigen levels have been made in acute PE and DVT with their subsequent increase after several weeks since the index event. Plasma fibrin clot proteome analysis confirms that clot-bound FXIII amounts associated with plasma FXIII activity are decreased in acute VTE. Reduced FXIII activity has been associated with impaired clot permeability and hypofibrinolysis in acute PE. The current review presents available studies on the role of FXIII in the modulation of fibrin clot properties during acute PE or DVT and following these events.
    [Show full text]
  • Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations
    Pleiotropic effects of antithrombin strand 1C substitution mutations. D A Lane, … , E Thompson, G Sas J Clin Invest. 1992;90(6):2422-2433. https://doi.org/10.1172/JCI116133. Research Article Six different substitution mutations were identified in four different amino acid residues of antithrombin strand 1C and the polypeptide leading into strand 4B (F402S, F402C, F402L, A404T, N405K, and P407T), and are responsible for functional antithrombin deficiency in seven independently ascertained kindreds (Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo) affected by venous thromboembolic disease. In all seven families, variant antithrombins with heparin-binding abnormalities were detected by crossed immunoelectrophoresis, and in six of the kindreds there was a reduced antigen concentration of plasma antithrombin. Two of the variant antithrombins, Rosny and Torino, were purified by heparin-Sepharose and immunoaffinity chromatography, and shown to have greatly reduced heparin cofactor and progressive inhibitor activities in vitro. The defective interactions of these mutants with thrombin may result from proximity of s1C to the reactive site, while reduced circulating levels may be related to s1C proximity to highly conserved internal beta strands, which contain elements proposed to influence serpin turnover and intracellular degradation. In contrast, s1C is spatially distant to the positively charged surface which forms the heparin binding site of antithrombin; altered heparin binding properties of s1C variants may therefore reflect conformational linkage between the reactive site and heparin binding regions of the molecule. This work demonstrates that point mutations in and immediately adjacent to strand 1C have multiple, or pleiotropic, […] Find the latest version: https://jci.me/116133/pdf Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations David A.
    [Show full text]
  • Human <X2-Macroblobulin and Plasmin. (459) Antithrombin III
    924 Abstracts added before the incubation of CPA positive plasma at 0° C for 20 hours. Addition of CIINH after CPA generation did not affect the shortened Thrombotest Time (TT). Synthetic amidino compounds (diOHstilbamidine, dibromopropamidine}, which have b een cla imed as sp ecific inhibitors of CI est e rase, were al so effective inhib i tors of CPA in final concentrations of l0- 4 - lO- • M . Alike to CliNH t h ey h ad no effect on a TT shortened by previous gen eration of CPA. In 8 subjects with CIINH d eficiency the shortening of t.he TT of plasma incubated at 0° C for 20 hours exeeeded that in a control group of 48 men and women not us ing oestrogenic drugs (p 0.05). CIINH activity proved to be consumed during CPA probably by binding of kallikrein, since purified CPA-kallikrein blocked purified CIINH activity. The antigen level of CIINH was n ot affected by CPA. This finding h as diagnostic importa nce since fal se low levels of CfiNH activity may b e detected in serum samples exp osed to CPA favouring conditions. In fact t his proved to be the case in a l arge proport ion of subjects t h ou ght to be suffering from so-called acquir ed angioneurotic oed em a (Quincke's oedema urticaria) on ground of low CfiNH activity determined in a frozen and thawed serum sample. C1INH activity proved to b e completely normal in fresh samples. P . Lambin, J. ll!J.. Fine, R. Audran and M.
    [Show full text]
  • Update on Antithrombin I (Fibrin)
    ©2007 Schattauer GmbH,Stuttgart AnniversaryIssueContribution Update on antithrombinI(fibrin) Michael W. Mosesson 1957–2007) The Blood Research Institute,BloodCenter of Wisconsin, Milwaukee,Wisconsin, USA y( Summary AntithrombinI(fibrin) is an important inhibitor of thrombin exosite 2.Thelatterreaction results in allostericchanges that generation that functions by sequestering thrombin in the form- down-regulate thrombin catalytic activity. AntithrombinIdefi- Anniversar ingfibrin clot,and also by reducing the catalytic activity of fibrin- ciency (afibrinogenemia), defectivethrombin binding to fibrin th boundthrombin.Thrombin binding to fibrin takesplace at two (antithrombin Idefect) found in certain dysfibrinogenemias (e.g. 50 classesofnon-substrate sites: 1) in thefibrin Edomain (two per fibrinogen Naples 1), or areduced plasma γ ’ chain content (re- molecule) throughinteractionwith thrombin exosite 1; 2) at a ducedantithrombin Iactivity),predispose to intravascular singlesite on each γ ’ chain through interaction with thrombin thrombosis. Keywords Fibrinogen,fibrin, thrombin, antithrombin I ThrombHaemost 2007; 98: 105–108 Introduction meric with respecttoits γ chains,and accounts for ~85% of human plasma fibrinogen. Thrombinbinds to its substrate, fibrinogen, through an anion- Low-affinity thrombin binding activity reflects thrombin ex- binding sitecommonlyreferred to as ‘exosite 1’ (1,2). Howell osite1bindinginEdomain of fibrin, as recentlydetailedbyana- recognized nearly acenturyago that the fibrin clot itself exhibits lysesofthrombin-fibrin
    [Show full text]
  • The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’S Perspective
    International Journal of Molecular Sciences Review The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective Hau C. Kwaan 1,* and Paul F. Lindholm 2 1 Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA 2 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] * Correspondence: [email protected] Abstract: The novel coronavirus disease (COVID-19) has many characteristics common to those in two other coronavirus acute respiratory diseases, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). They are all highly contagious and have severe pulmonary complications. Clinically, patients with COVID-19 run a rapidly progressive course of an acute respiratory tract infection with fever, sore throat, cough, headache and fatigue, complicated by severe pneumonia often leading to acute respiratory distress syndrome (ARDS). The infection also involves other organs throughout the body. In all three viral illnesses, the fibrinolytic system plays an active role in each phase of the pathogenesis. During transmission, the renin-aldosterone- angiotensin-system (RAAS) is involved with the spike protein of SARS-CoV-2, attaching to its natural receptor angiotensin-converting enzyme 2 (ACE 2) in host cells. Both tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1) are closely linked to the RAAS. In lesions in the lung, kidney and other organs, the two plasminogen activators urokinase-type plasminogen activator (uPA) and tissue plasminogen activator (tPA), along with their inhibitor, plasminogen activator 1 (PAI-1), are involved. The altered fibrinolytic balance enables the development of a hypercoagulable Citation: Kwaan, H.C.; Lindholm, state.
    [Show full text]
  • 2: Genetic Aspects of a Antitrypsin Deficiency
    259 REVIEW SERIES Thorax: first published as 10.1136/thx.2003.006502 on 25 February 2004. Downloaded from a1-Antitrypsin deficiency ? 2: Genetic aspects of a1- antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk D L DeMeo, E K Silverman ............................................................................................................................... Thorax 2004;59:259–264. doi: 10.1136/thx.2003.006502 The genetic aspects of AAT deficiency and the variable globin locus which results in haemoglobin S. This mutant haemoglobin assumes a sickle shape manifestations of lung disease in PI Z individuals are when deoxygenated, causing an array of clinical reviewed. The role of modifying genetic factors which may consequences. However, affected individuals interact with environmental factors (such as cigarette vary widely in disease severity. One known genetic modifier of sickle cell disease is heredi- smoking) is discussed, and directions for future research tary persistence of fetal haemoglobin in which are presented. continued production of Hb F impairs sickling ........................................................................... and limits disease severity. In pulmonary medicine, cystic fibrosis and AAT deficiency—classic monogenic disorders he susceptibility to develop chronic obstruc- that display marked variability in disease sus- tive pulmonary disease (COPD) results from ceptibility—demonstrate elements of genetic Ta combination of genetic and environmental complexity. In severe AAT deficiency the Z factors. The most important environmental risk mutation leads to low serum protein levels, but factor for COPD is cigarette smoking, but PI Z individuals vary markedly in lung and liver individuals vary in their susceptibility to the disease development and severity. The altered effects of cigarette smoke and only a minority of AAT protein is the product of a single gene, but smokers will develop COPD.
    [Show full text]
  • Alpha -Antitrypsin Deficiency
    The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Alpha1-Antitrypsin Deficiency Pavel Strnad, M.D., Noel G. McElvaney, D.Sc., and David A. Lomas, Sc.D.​​ lpha1-antitrypsin (AAT) deficiency is one of the most common From the Department of Internal Med­ genetic diseases. Most persons carry two copies of the wild-type M allele icine III, University Hospital RWTH of SERPINA1, which encodes AAT, and have normal circulating levels of the (Rheinisch–Westfälisch Technische Hoch­ A schule) Aachen, Aachen, Germany (P.S.); protein. Ninety-five percent of severe cases of AAT deficiency result from the homo- the Irish Centre for Genetic Lung Dis­ zygous substitution of a single amino acid, Glu342Lys (the Z allele), which is present ease, Royal College of Surgeons in Ire­ in 1 in 25 persons of European descent (1 in 2000 persons of European descent land, Beaumont Hospital, Dublin (N.G.M.); and UCL Respiratory, Division of Medi­ are homozygotes). Mild AAT deficiency typically results from a different amino cine, Rayne Institute, University College acid replacement, Glu264Val (the S allele), which is found in 1 in 4 persons in the London, London (D.A.L.). Address re­ Iberian peninsula. However, many other alleles have been described that have vari- print requests to Dr. Lomas at UCL Re­ spiratory, Rayne Institute, University Col­ able effects, such as a lack of protein production (null alleles), production of mis- lege London, London WC1E 6JF, United folded protein, or no effect on the level or function of circulating AAT (Table 1). Kingdom, or at d .
    [Show full text]
  • The Plasmin–Antiplasmin System: Structural and Functional Aspects
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bern Open Repository and Information System (BORIS) Cell. Mol. Life Sci. (2011) 68:785–801 DOI 10.1007/s00018-010-0566-5 Cellular and Molecular Life Sciences REVIEW The plasmin–antiplasmin system: structural and functional aspects Johann Schaller • Simon S. Gerber Received: 13 April 2010 / Revised: 3 September 2010 / Accepted: 12 October 2010 / Published online: 7 December 2010 Ó Springer Basel AG 2010 Abstract The plasmin–antiplasmin system plays a key Plasminogen activator inhibitors Á a2-Macroglobulin Á role in blood coagulation and fibrinolysis. Plasmin and Multidomain serine proteases a2-antiplasmin are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into solu- Abbreviations ble fragments. However, besides plasmin(ogen) and A2PI a2-Antiplasmin, a2-Plasmin inhibitor a2-antiplasmin the system contains a series of specific CHO Carbohydrate activators and inhibitors. The main physiological activators EGF-like Epidermal growth factor-like of plasminogen are tissue-type plasminogen activator, FN1 Fibronectin type I which is mainly involved in the dissolution of the fibrin K Kringle polymers by plasmin, and urokinase-type plasminogen LBS Lysine binding site activator, which is primarily responsible for the generation LMW Low molecular weight of plasmin activity in the intercellular space. Both activa- a2M a2-Macroglobulin tors are multidomain serine proteases. Besides the main NTP N-terminal peptide of Pgn physiological inhibitor a2-antiplasmin, the plasmin–anti- PAI-1, -2 Plasminogen activator inhibitor 1, 2 plasmin system is also regulated by the general protease Pgn Plasminogen inhibitor a2-macroglobulin, a member of the protease Plm Plasmin inhibitor I39 family.
    [Show full text]
  • Prolastin.18 the Mean in Vivo Recovery 18,19 of Alpha1-PI Was 4.2 Mg (Immunologic)/Dl Per Mg (Functional)/Kg Body Weight Administered
    08937789 (Rev. January 2005) ipated in a study of acute and/or chronic replacement therapy with Prolastin.18 The mean in vivo recovery 18,19 of alpha1-PI was 4.2 mg (immunologic)/dL per mg (functional)/kg body weight administered. The 18,19 Alpha1-Proteinase Inhibitor (Human) half-life of alpha1-PI in vivo was approximately 4.5 days. Based on these observations, a program of chronic replacement therapy was developed. Nineteen of the subjects in these studies received w Prolastin replacement therapy, 60 mg/kg body weight, once weekly for up to 26 weeks (average 24 weeks Prolastin of therapy). With this schedule of replacement therapy, blood levels of alpha1-PI were maintained above 18-20 80 mg/dL (based on the commercial standards for alpha1-PI immunologic assay). Within a few FOR INTRAVENOUS USE ONLY weeks of commencing this program, bronchoalveolar lavage studies demonstrated significantly increased levels of alpha -PI and functional antineutrophil elastase capacity in the epithelial lining fluid 1 5 8 1 of the lower respiratory tract of the lung, as compared to levels prior to commencing the program of 18-20 chronic replacement therapy with Alpha1-Proteinase Inhibitor (Human), Prolastin. All 23 individuals who participated in the investigations were immunized with Hepatitis B Vaccine and received a single dose of Hepatitis B Immune Globulin (Human) on entry into the investigation. Although no other steps were taken to prevent hepatitis, neither hepatitis B nor non-A, non-B hepatitis occurred in any of the subjects.18,19 All subjects remained seronegative for HIV antibody. None of the subjects developed any detectable antibody to alpha1-PI or other serum protein.
    [Show full text]
  • RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen
    [Show full text]
  • Fibrin Induces Release of Von Willebrand Factor from Endothelial Cells
    Fibrin induces release of von Willebrand factor from endothelial cells. J A Ribes, … , C W Francis, D D Wagner J Clin Invest. 1987;79(1):117-123. https://doi.org/10.1172/JCI112771. Research Article Addition of fibrinogen to human umbilical vein endothelial cells in culture resulted in release of von Willebrand factor (vWf) from Weibel-Palade bodies that was temporally related to formation of fibrin in the medium. Whereas no release occurred before gelation, the formation of fibrin was associated with disappearance of Weibel-Palade bodies and development of extracellular patches of immunofluorescence typical of vWf release. Release also occurred within 10 min of exposure to preformed fibrin but did not occur after exposure to washed red cells, clot liquor, or structurally different fibrin prepared with reptilase. Metabolically labeled vWf was immunopurified from the medium after release by fibrin and shown to consist of highly processed protein lacking pro-vWf subunits. The contribution of residual thrombin to release stimulated by fibrin was minimized by preparing fibrin clots with nonstimulatory concentrations of thrombin and by inhibiting residual thrombin with hirudin or heating. We conclude that fibrin formed at sites of vessel injury may function as a physiologic secretagogue for endothelial cells causing rapid release of stored vWf. Find the latest version: https://jci.me/112771/pdf Fibrin Induces Release of von Willebrand Factor from Endothelial Cells Julie A. Ribes, Charles W. Francis, and Denisa D. Wagner Hematology Unit, Department ofMedicine, University ofRochester School ofMedicine and Dentistry, Rochester, New York 14642 Abstract erogeneous and can be separated by sodium dodecyl sulfate (SDS) electrophoresis into a series of disulfide-bonded multimers Addition of fibrinogen to human umbilical vein endothelial cells with molecular masses from 500,000 to as high as 20,000,000 in culture resulted in release of von Willebrand factor (vWf) D (8).
    [Show full text]
  • The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
    RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection.
    [Show full text]